Fortrea Expands Board Of Directors With Appointment Of Healthcare Industry Veteran William Sharbaugh

Fortrea, traded on Nasdaq under the symbol FTRE, has announced the appointment of William Sharbaugh to its Board of Directors. The company, a leading global contract research organization, noted that Sharbaugh brings more than 30 years of experience in the pharmaceutical industry to the role. 

Throughout his career, he has held a variety of executive and board positions, building expertise in finance, operations, manufacturing, and quality. Fortrea stated that his extensive background and leadership experience will support the company’s ongoing efforts to strengthen its governance and drive growth in the competitive healthcare and life sciences sector.

Anshul Thakral, CEO of Fortrea, “I’m delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations. He is a highly respected leader, who understands our stakeholders and what it takes to deliver high-quality drug development globally. Bill’s experience and leadership acumen will be valuable to Fortrea as we execute on our plans. His track record of success demonstrates his dedication to our purpose of delivering life-changing treatments to patients faster.”

Mr. Sharbaugh stated, “I’m looking forward to joining Fortrea’s Board as the company focuses on the future as a trusted partner to its clients. With my experience in both CRO and pharmaceutical companies, I hope to offer practical and pragmatic perspectives to the Board. I look forward to partnering with Anshul, the Board and the Fortrea team to create value for all stakeholders.”